Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy.
about
Current and emerging treatment strategies for Duchenne muscular dystrophyFluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice.Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibitionNeuropsychological and physiological correlates of fatigue following traumatic brain injury.GSNOR Deficiency Enhances In Situ Skeletal Muscle Strength, Fatigue Resistance, and RyR1 S-Nitrosylation Without Impacting Mitochondrial Content and Activity.Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms.nNOS regulation of skeletal muscle fatigue and exercise performance.Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy.Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.Transient receptor potential channel 6 regulates abnormal cardiac S-nitrosylation in Duchenne muscular dystrophy.
P2860
Q26741535-28CAFD3B-B549-4CB4-9FF8-2EB8F18F405FQ33991780-BBF1E11A-025C-4F52-9ED5-0F83E9A774B0Q34764061-797DED82-7FAC-43AF-855F-8903A68FDBE5Q34765802-EACC65DC-D4EF-4093-8CF2-5CD833A6CB17Q35986842-D68C99DE-B5B5-48C6-A68A-637540E8F58DQ36422465-097CF28B-2933-4DD9-93A0-AC55B3E50702Q36467072-DA2DEDAE-EEE9-45AA-8488-97EE851A3B50Q38190625-D063EE7F-2998-4EFE-9322-77EC29D83AA8Q38412593-7C2A0B61-C83E-4AE9-9E61-826DD388596FQ38412804-1772BCD5-B709-453F-BC22-3265C16AC04AQ39310461-21DC4D0A-AD24-40E0-8676-F7B133C0CA0AQ40813682-2DE0A752-2641-40B8-88C9-FCEDAA8F1115Q41031903-01A12390-AD9F-46FA-98FC-BE6E74B6EB27Q47350159-5B3A868E-C63A-4894-9FD7-24DAFF8EA339
P2860
Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of the therapeutic ...... f duchenne muscular dystrophy.
@en
Evaluation of the therapeutic ...... f duchenne muscular dystrophy.
@nl
type
label
Evaluation of the therapeutic ...... f duchenne muscular dystrophy.
@en
Evaluation of the therapeutic ...... f duchenne muscular dystrophy.
@nl
prefLabel
Evaluation of the therapeutic ...... f duchenne muscular dystrophy.
@en
Evaluation of the therapeutic ...... f duchenne muscular dystrophy.
@nl
P2093
P2860
P1476
Evaluation of the therapeutic ...... f duchenne muscular dystrophy.
@en
P2093
Candace M Adamo
Joseph A Beavo
Justin M Percival
Stanley C Froehner
P2860
P304
P356
10.1007/978-3-642-17969-3_14
P577
2011-01-01T00:00:00Z